STERIS (STE) investor relations material

Key business insights and market dynamics

• Demand for products and services in healthcare remains resilient and essential, with hospitals relying on sterile processing to maintain procedure volumes and revenue.

• Procedure growth is at the lower end of the typical range but remains positive, with endoscopy procedures showing strong growth of 7–8.5% due to expanded screening and rising early-onset colon cancer.

• Recurring revenue now constitutes 80% of the business, supporting stable mid to high single-digit top-line growth and double-digit bottom-line growth.

• Market share expansion, especially in Europe, and new product introductions are expected to drive future growth.

• Healthcare services and AST (sterilization) businesses are structurally driven by procedure volume, equipment maintenance, and specialized device requirements.

Growth drivers and operational strategy

• Top-line growth is fueled by pricing, procedure volume, share gains, and occasional bolt-on M&A, resulting in mid to high single-digit growth.

• Healthcare services growth is supported by equipment maintenance contracts and third-party device repair, providing value through asset longevity.

• AST business benefits from global footprint and ability to handle sophisticated device sterilization, with normalization expected after inventory destocking.

• Life sciences segment sees steady growth in consumables for aseptic manufacturing, with capital equipment orders adding some variability.

• Major investment in a new North Carolina facility will expand capacity, automate production, and support high-margin chemistry businesses.

Margin expansion, capital allocation, and outlook

• Margin expansion is expected from pricing power, volume leverage in high fixed-cost businesses, automation, and continued shift to recurring revenue.

• Free cash flow has improved, supporting a balanced capital allocation strategy: dividends, organic investment, disciplined M&A, and share buybacks.

• Geographic expansion, especially in Europe, remains a focus, with organic growth prioritized over acquisitions unless strategic opportunities arise.

• Key performance indicators to watch include consumables growth in healthcare, inventory normalization in AST, and continued differentiation in customer outcomes.

• Five-year goals target 7% top-line and 11% bottom-line growth, with confidence in achieving similar customer impact in Europe as in North America.